Pharma Stock Roundup: LLYs CFO Departs, ABBV, AZN Drugs Get CHMP Approval
Eli Lillys (LLY) CFO Anat Ashkenazi resigns. CHMP recommends the expanded use of AbbVies (ABBV) Skyrizi and AstraZenecas (AZN) Tagrisso.…
61,750€
2,07%
Echtzeit-Aktienkurs Astrazeneca PLC (Spons. ADRs)
Bid:
Ask:
Nachrichten zur Astrazeneca PLC (Spons. ADRs) Aktie
Summit Therapeutics, AstraZeneca And More From The Year’s Biggest Cancer Conference
Plus: Annie Lamont, Robert Nelsen, Hemant Taneja and more healthtech venture capital investors on this years Forbes Midas list.…
Acquisition of Fusion completed
05 June 2024
Acquisition of Fusion completed
AstraZeneca today announced the successful completion of the acquisition of Fusion Pharmaceuticals Inc., a clinical-stage…
Why CEO AstraZeneca believes the drugmaker can almost double revenue by 2030
AstraZeneca CEO Pascal Soriot discussed his companys ambitious revenue goal with CNBCs Jim Cramer.…
Total Voting Rights
3 June 2024 15:00 BST
Transparency Directive
Voting rights and capital
The following notification is made in accordance with the UK Financial Conduct…
AstraZeneca’s Lung, Breast Cancer Drugs Markedly Slow Disease
AstraZeneca Plc’s lung and breast cancer drugs significantly slowed the spread of disease in two trials, potentially establishing the medicines…
J&J says Rybrevant combo bests AstraZenecas Tagrisso in type of lung cancer
…
Global Dyspepsia Drugs Market Size To Worth Exceed USD 14.7 Billion By 2033 | CAGR Of 4.46%
The Global Dyspepsia Drugs Market Size was Valued at USD 9.5 Billion in 2023 and the Worldwide Dyspepsia Drugs Market…
This Pharma Stock Is Poised to Keep Outperforming the S&P 500
AstraZeneca has quietly delivered market-beating results since 2014. Despite skepticism, the company should be able to repeat this feat over…
This Pharma Stock Is Poised to Keep Outperforming the S&P 500 @themotleyfool #stocks $AZN
AstraZeneca has quietly delivered market-beating results since 2014. Despite skepticism, the company should be able to repeat this feat over…